Aptar Q1 Sales Jump 11% to Beat Estimates, Despite EPS Decline
ATR sits 20% above its 52-week low of $103.227.
Summary
AptarGroup reported Q1 sales that rose 11% to $982.90 million, surpassing analyst estimates of $955.28 million. Adjusted EPS of $1.19 also beat consensus of $1.15, although it declined 8% year-over-year, while unadjusted EPS fell to $1.12. This earnings report provides the actual Q1 performance, following the company's recent announcement of Q2 adjusted EPS guidance ranging from $1.32 to $1.40. The strong sales growth, fueled by robust demand in injectables (including GLP-1 and biologics) and consumer dispensing, indicates solid underlying business momentum. However, the decline in prescription division sales due to emergency medicine destocking presents a mixed financial picture. Traders will be evaluating the company's ability to maintain growth in its high-demand segments and navigate potential supply-chain uncertainties in the upcoming quarter.
At the time of this announcement, ATR was trading at $123.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $103.23 to $164.28. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.